Jazz Pharmaceuticals Announced Presentation of Phase 3 Study Results of Xywav Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting; Says Xywav Demonstrated Statistically Significant Differences in Change in Epworth Sleepiness Scale Score